Business Context and Reporting Period
This Form 8-K is a current report filed by Derycz Scientific, Inc. (not Research Solutions, Inc.) on December 22, 2010, regarding unregistered sales of equity securities. The report details warrant exercises and new warrant issuances occurring between November 12, 2010, and December 22, 2010.
Key Financial Metrics and Capital Activity
- Cash Proceeds: The Company received an additional $626,375 in cash from the exercise of December 2006 Warrants.
- Share Issuance (Cash Exercise): 501,100 shares of common stock were issued upon cash exercise of the December 2006 Warrants.
- Share Issuance (Cashless Exercise): 305,900 shares of common stock were issued under cashless exercise provisions.
- New Warrants Issued: 7 new warrants were issued, representing the right to purchase 250,550 shares at an exercise price of $2.00 per share, expiring November 17, 2013.
- Consultant Warrants: Warrants to purchase 400,000 shares were issued to consultants (100,000 at $1.75/share; 300,000 at $2.25/share).
- Use of Proceeds: Funds from cash exercises are designated for general working capital purposes.
Material Changes and Events
Following a previous report on November 19, 2010, an additional 7 of the December 2006 Warrants were exercised. These original warrants had an exercise price of $1.25 and expired on December 22, 2010. The remaining 5 unexercised December 2006 Warrants (covering 69,250 shares) expired on this date and are no longer exercisable. The Company also issued new warrants to consultants for services to be rendered, vesting over a one-year period.
Outlook, Risks, and Contingencies
- Registration Status: Neither the New Warrants nor the Consultant Warrants, nor the underlying shares, have been registered under the Securities Act of 1933.
- Future Registration: The Company intends to use best efforts to register the shares underlying the New Warrants during 2011 but is not subject to penalties for failure to do so.
- Exemption Reliance: Sales were made in reliance on Section 4(2) of the Securities Act or Regulation D, with no general solicitation used and purchasers deemed "accredited investors."
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance (501,100 cash + 305,900 cashless + 400,000 consultant warrants).
- Confirm the dilution impact of the 993,675 shares issuable upon exercise of the New Warrants.
- Review the Company's 2011 filings to confirm if the registration of underlying shares for the New Warrants was completed.
- Assess the impact of the $626,375 cash infusion on the Company's liquidity and working capital needs.